Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick-borne encephalitis virus
Open Access
- 15 April 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (4) , e1009505
Abstract
The Tick-borne encephalitis virus (TBEV) causes different disease symptoms varying from asymptomatic infection to severe encephalitis and meningitis suggesting a crucial role of the human host immune system in determining the fate of the infection. There is a need to understand the mechanisms underpinning TBEV-host interactions leading to protective immunity. To this aim, we studied the response of human peripheral blood mononuclear cells (PBMC) to the whole formaldehyde inactivated TBEV (I-TBEV), the drug substance of Encepur, one of the five commercially available vaccine. Immunophenotyping, transcriptome and cytokine profiling of PBMC revealed that I-TBEV generates differentiation of a sub-population of plasmacytoid dendritic cells (pDC) that is specialized in type I interferon (IFN) production. In contrast, likely due to the presence of aluminum hydroxide, Encepur vaccine was a poor pDC stimulus. We demonstrated I-TBEV-induced type I IFN together with Interleukin 6 and BAFF to be critical for B cell differentiation to plasmablasts as measured by immunophenotyping and immunoglobulin production. Robust type I IFN secretion was induced by pDC with the concerted action of both viral E glycoprotein and RNA mirroring previous data on dual stimulation of pDC by both S. aureus and influenza virus protein and nucleic acid that leads to a type I IFN-mediated sustained immune response. E glycoprotein neutralization or high temperature denaturation and inhibition of Toll-like receptor 7 signalling confirmed the importance of preserving the functional integrity of these key viral molecules during the inactivation procedure and manufacturing process to produce a vaccine able to stimulate strong immune responses.Keywords
Funding Information
- Innovative Medicine Initiative (115924)
This publication has 73 references indexed in Scilit:
- Mechanism of Immunopotentiation and Safety of Aluminum AdjuvantsFrontiers in Immunology, 2013
- EBV stimulates TLR‐ and autophagy‐dependent pathways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escapeEuropean Journal of Immunology, 2012
- Prevalence of tick borne encephalitis virus in tick nymphs in relation to climatic factors on the southern coast of NorwayParasites & Vectors, 2012
- Systems biology of vaccination for seasonal influenza in humansNature Immunology, 2011
- The current perspective on tick-borne encephalitis awareness and prevention in six Central and Eastern European countries: Report from a meeting of experts convened to discuss TBE in their regionVaccine, 2011
- Tick-borne encephalitis after vaccination: Vaccine failure or misdiagnosisVaccine, 2010
- Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonistsBlood, 2010
- Interferon-inducible antiviral effectorsNature Reviews Immunology, 2008
- Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cellsJournal of Experimental Medicine, 2008
- Plasmacytoid dendritic cell–specific receptor ILT7–FcεRIγ inhibits Toll-like receptor–induced interferon productionJournal of Experimental Medicine, 2006